Edition:
United Kingdom

People: Achillion Pharmaceuticals Inc (ACHN.OQ)

ACHN.OQ on NASDAQ Stock Exchange Global Select Market

4.65USD
19 Aug 2019
Change (% chg)

$-0.12 (-2.52%)
Prev Close
$4.77
Open
$4.86
Day's High
$4.90
Day's Low
$4.57
Volume
273,126
Avg. Vol
420,558
52-wk High
$5.02
52-wk Low
$1.29

Graves, Kurt 

Mr. Kurt C. Graves serves as Independent Director of Achillion Pharmaceuticals, Inc., with effect from June 11, 2012. Mr. Graves has served as Executive Chairman and Chief Executive Officer of Intarcia Therapeutics, a biotechnology company, since September 2010. Prior to joining Intarcia Therapeutics, Mr. Graves served as Executive Vice President, Chief Commercial Officer and Head of Corporate and Strategic Development at Vertex Pharmaceuticals, a pharmaceutical company, from July 2007 to November 2009. From January 1999 to July 2007, Mr. Graves held various leadership positions at Novartis AG, a pharmaceutical company, most recently as Global Head of the General Medicines Business Unit and Chief Marketing Officer for the Pharmaceuticals division. Prior to Novartis, Mr. Graves held commercial and general management positions of increasing responsibility at Merck & Co., Inc., a global health care company, and Astra Merck Pharmaceuticals. Since August 2010, Mr. Graves has served as Chairman of the Board of Intarcia Therapeutics, a private biopharmaceutical company and also has served as Chairman of the Board at Radius Health, Inc., a publicly traded biopharmaceutical company since May 2011. Since October 2015, Mr. Graves has also served on the Board of Directors of Seres Therapeutics, Inc., a publicly traded biotechnology company, creating a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome. Mr. Graves earned his B.S. in Biology from Hillsdale College and has attended executive leadership programs at Harvard, Wharton School of Management and University of Michigan. Mr. Graves has more than 20 years of U.S. and global general management experience in top-tier U.S. and European based pharmaceutical and biotech companies.

Basic Compensation

Total Annual Compensation, USD 71,875
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 87,037
Fiscal Year Total, USD 158,912

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --